ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

IL17A

interleukin 17A · also IL-17A, IL-17, CTLA8, IL17 · Interleukins

9 programs in company-led studies act on IL17A, from 7 companies: 2 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
secukinumabruleNovartis–phase 41284 running–NCIt
vunakizumabruleJiangsu HengRui Medicineinhibitorphase 4174 running–ChEMBL
ixekizumabruleEli Lillyinhibitorphase 4383 running–ChEMBL
bimekizumabruleUCBinhibitorphase 3437 runningIL17FChEMBL
sonelokimabruleMoonLake Immunotherapeuticsinhibitorphase 3124 runningIL17FChEMBL
SCT650CruleSinocelltech Group–phase 233 running–the studies' text
tibulizumabruleEli Lillyinhibitorphase 252 runningTNFSF13BChEMBL
simepdekinraEli Lillyinhibitorphase 270 running–a judged reading
UA026ruleUsynova Pharmaceuticalsinhibitorphase 111 running–the studies' text

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.